A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Staphylococcus aureus produces hospital- and community-acquired infections, with methicillin-resistant S. aureus posing a serious public health threat. The golden carotenoid pigment of S. aureus , staphyloxanthin, promotes resistance to reactive oxygen species and host neutrophil-based killing, and early enzymatic steps in staphyloxanthin production resemble those for cholesterol biosynthesis. We determined the crystal structures of S. aureus dehydrosqualene synthase (CrtM) at 1.58 angstrom resolution, finding structural similarity to human squalene synthase (SQS). We screened nine SQS inhibitors and determined the structures of three, bound to CrtM. One, previously tested for cholesterol-lowering activity in humans, blocked staphyloxanthin biosynthesis in vitro (median inhibitory concentration ∼100 nM), resulting in colorless bacteria with increased susceptibility to killing by human blood and to innate immune clearance in a mouse infection model. This finding represents proof of principle for a virulence factor–based therapy against S. aureus .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To combat ROS, S. aureus uses a number of defensive molecules, including catalase (KatA), superoxide dismutases (SodA/M), and the golden pigment staphyloxanthin (36–44).”
From Staphylococcus aureus Adapts to Oxidative Stress by Producing H 2 O 2 -Resistant Small-Colony Variants via the SOS Response (2015) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is important because the generation of reactive oxygen species (ROS) such as O2− and H2O2 by neutrophils is a crucial host defense mechanism against S. aureus (36, 37).”
From Staphylococcus aureus Adapts to Oxidative Stress by Producing H 2 O 2 -Resistant Small-Colony Variants via the SOS Response (2015) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Liu, G. Y., Essex, A., Buchanan, J. T., Datta, V., Hoffman, H. M., Bastian, J. F., Fierer, J., & Nizet, V. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050846 · Cited by 752
Self-citationClauditz, A., Resch, A., Wieland, K.-P., Peschel, A., & Götz, F. (2006) · Infection and Immunity · doi:10.1128/iai.00204-06 · Cited by 509
Lyon, G. J., Mayville, P., Muir, T. W., & Novick, R. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13330 · Cited by 263
Crystal Structure of Human Squalene Synthase
Pandit, J., Danley, D. E., Schulte, G. K., Mazzalupo, S., Pauly, T. A., Hayward, C. M., Hamanaka, E. S., Thompson, J. F., & Harwood, H. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004132200 · Cited by 238
Bisphosphonates target multiple sites in both cis - and trans -prenyltransferases
Guo, R.-T., Cao, R., Liang, P.-H., Ko, T.-P., Chang, T.-H., Hudock, M. P., Jeng, W.-Y., Chen, C. K.-M., Zhang, Y., Song, Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702254104 · Cited by 184
Self-citationBacterial virulence as a target for antimicrobial chemotherapy
Alksne, L. E., & Projan, S. J. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00155-5 · Cited by 158
Antimicrobial Resistance: It's Not Just for Hospitals
Bancroft, E. A. (2007) · JAMA · doi:10.1001/jama.298.15.1803 · Cited by 141
Anchor Structure of Staphylococcal Surface Proteins
Ton-That, H., & Schneewind, O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24316 · Cited by 140
Research works printed but not linked: 1
- National Research Council, in Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics (National Academies Press, Washington, DC, 2006), pp. 21–22.
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Structural and Chemical Biology of Terpenoid Cyclases
Christianson, D. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00287 · Cited by 1,223
Sticking together: building a biofilm the Bacillus subtilis way
Vlamakis, H., Chai, Y., Beauregard, P., Losick, R., & Kolter, R. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2960 · Cited by 1,036
Insights into Secondary Metabolism from a Global Analysis of Prokaryotic Biosynthetic Gene Clusters
Cimermancic, P., Medema, M. H., Claesen, J., Kurita, K., Wieland Brown, L. C., Mavrommatis, K., Pati, A., Godfrey, P. A., Koehrsen, M., Clardy, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.034 · Cited by 981
“, 2005) and systemic infection (Liu et al., 2008).”
BackgroundFey, P. D., Endres, J. L., Yajjala, V. K., Widhelm, T. J., Boissy, R. J., Bose, J. L., & Bayles, K. W. (2013) · mBio · doi:10.1128/mbio.00537-12 · Cited by 973
“The biosynthetic pathway leading to staphyloxanthin has been characterized, and the associated genes have been identified (27, 28).”
BackgroundLangdon, A., Crook, N., & Dantas, G. (2016) · Genome Medicine · doi:10.1186/s13073-016-0294-z · Cited by 912
Reactive Oxygen Species and Neutrophil Function
Winterbourn, C. C., Kettle, A. J., & Hampton, M. B. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014442 · Cited by 885
“aureus, staphyloxanthin, is a virulence factor that acts as an oxidant scavenger (81), but this is in doubt because the virulence of a nonpigmented clone was not augmented when staphyloxanthin synthesis was introduced (82).”
BackgroundRole of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Targeting virulence: can we make evolution-proof drugs?
Allen, R. C., Popat, R., Diggle, S. P., & Brown, S. P. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3232 · Cited by 532
Plant Natural Products Targeting Bacterial Virulence Factors
Silva, L. N., Zimmer, K. R., Macedo, A. J., & Trentin, D. S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00184 · Cited by 504
Redox Reactions and Microbial Killing in the Neutrophil Phagosome
Winterbourn, C. C., & Kettle, A. J. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4827 · Cited by 468
“Other organisms may resist toxic oxidants with virulence factors, such as release of superoxide dismutase (20, 112, 117) or production of the carotenoid staphyloxanthin (120), or upregulate protective mechanisms in response to an oxidant stress (85).”
Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production
Brynildsen, M. P., Winkler, J. A., Spina, C. S., MacDonald, I. C., & Collins, J. J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2458 · Cited by 470
Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling
York, A. G., Williams, K. J., Argus, J. P., Zhou, Q. D., Brar, G., Vergnes, L., Gray, E. E., Zhen, A., Wu, N. C., Yamada, D. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.045 · Cited by 461
Terpene Biosynthesis: Modularity Rules
Oldfield, E., & Lin, F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201103110 · Cited by 391
Self-citationColor me bad: microbial pigments as virulence factors
Liu, G. Y., & Nizet, V. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2009.06.006 · Cited by 378
“Theoretical advantages of this therapeutic approach would lie in specificity, because the drug would not exert unwanted effects on the normal microflora, and reduced selective pressure for resistance, because the drug only exerts its killing effect in the disease context of an activated host immune response [4, 6 ].”
BackgroundInfluentialSelf-citationCholesterol Biosynthesis: A Mechanistic Overview
Cerqueira, N. M. F. S. A., Oliveira, E. F., Gesto, D. S., Santos-Martins, D., Moreira, C., Moorthy, H. N., Ramos, M. J., & Fernandes, P. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00342 · Cited by 352
Functional microdomains in bacterial membranes
López, D., & Kolter, R. (2010) · Genes & Development · doi:10.1101/gad.1945010 · Cited by 346
“When we deleted the gene yisP in the strain harboring the chimera KinC–DegS, the response of the chimeric kinase (inhibition of motility) was not observed when nystatin was present (Supplemental Fig.”
BackgroundMethodInfluentialPalmer, K. L., Godfrey, P., Griggs, A., Kos, V. N., Zucker, J., Desjardins, C., Cerqueira, G., Gevers, D., Walker, S., Wortman, J., et al. (2012) · mBio · doi:10.1128/mbio.00318-11 · Cited by 337
“Streptococcus aureus also produces a carotenoid pigment and virulence factor, staphyloxanthin, that protects it from host-induced oxidative damage and antimicrobial peptides, and inhibitors show promise as novel therapeutics (36).”
BackgroundMechanistic Aspects of Carotenoid Biosynthesis
Moise, A. R., Al-Babili, S., & Wurtzel, E. T. (2014) · Chemical Reviews · doi:10.1021/cr400106y · Cited by 327
Bayer, A. S., Schneider, T., & Sahl, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06819.x · Cited by 311
Emerging nanotechnology-based strategies for the identification of microbial pathogenesis
Kaittanis, C., Santra, S., & Perez, J. M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.013 · Cited by 308
Anisha, B. S., Biswas, R., Chennazhi, K. P., & Jayakumar, R. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.09.011 · Cited by 295
Microbiota-Targeted Therapies: An Ecological Perspective
Lemon, K. P., Armitage, G. C., Relman, D. A., & Fischbach, M. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004183 · Cited by 286
“aureus but makes the bacterium more sensitive to innate immune clearance in an animal model of infection (42).”
BackgroundFunctions, Therapeutic Applications, and Synthesis of Retinoids and Carotenoids
Álvarez, R., Vaz, B., Gronemeyer, H., & de Lera, Á. R. (2014) · Chemical Reviews · doi:10.1021/cr400126u · Cited by 260
The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
Xia, Y., Xie, Y., Yu, Z., Xiao, H., Jiang, G., Zhou, X., Yang, Y., Li, X., Zhao, M., Li, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.070 · Cited by 257
“(B) Chemical structures of FPPS inhibitor TH-Z93, GGPPS inhibitor TH-Z145, and the SQS inhibitor BPH-652.”
InfluentialSelf-citationStaphylococcal response to oxidative stress
Gaupp, R., Ledala, N., & Somerville, G. A. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00033 · Cited by 253
“In a mouse subcutaneous abscess model as well as a systemic S. aureus infection model, non-pigmented S. aureus have reduced virulence and survival relative to the pigmented wildtype strain (Liu et al., 2005, 2008).”
BackgroundInfluentialAntibiotics in the clinical pipeline as of December 2022
Butler, M. S., Henderson, I. R., Capon, R. J., & Blaskovich, M. A. T. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-023-00629-8 · Cited by 239
“Staphyloxanthin is a golden colored carotenoid with antioxidant activity that helps to neutralize reactive oxygen species (ROS) secreted by neutrophils, which protects bacteria [316, 317].”
BackgroundMembrane Microdomain Disassembly Inhibits MRSA Antibiotic Resistance
García-Fernández, E., Koch, G., Wagner, R. M., Fekete, A., Stengel, S. T., Schneider, J., Mielich-Süss, B., Geibel, S., Markert, S. M., Stigloher, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.012 · Cited by 243
“S. aureususes the mevalonate pathway to produce staphyloxanthin; thus, statins inhibit staphyloxanthin biosynthesis (Liu et al., 2008) (Figure S6D).”
BackgroundMiller, L. S., Fowler, V. G., Shukla, S. K., Rose, W. E., & Proctor, R. A. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz030 · Cited by 240
“aureus produces superoxide dismutase enzymes and the golden carotenoid pigment, staphyloxanthin, as potent antioxidants that inhibit reactive oxygen species (ROS) mediated neutrophil killing (Karavolos et al. 2003; Liu et al. 2005; Liu et al. 2008).”
BackgroundA Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies
Birt, M. C., Anderson, D. W., Bruce Toby, E., & Wang, J. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2016.10.004 · Cited by 238
Mechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 234
Molecular Pathogenesis of Staphylococcus aureus Infection
Liu, G. Y. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819dc44d · Cited by 220
Self-citationMishra, N. N., Liu, G. Y., Yeaman, M. R., Nast, C. C., Proctor, R. A., McKinnell, J., & Bayer, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-10 · Cited by 202
“aureus, potentially by detoxifying reactive oxygen species produced by phagocytes (19).”
BackgroundInfluentialSelf-citationExploring the Existence of Lipid Rafts in Bacteria
Bramkamp, M., & Lopez, D. (2015) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00036-14 · Cited by 188
“CrtM likely converts two molecules of farnesylpyrophosphate into squalene or dehydrosqualene, depending on whether the reaction includes or does not include NADPH as a reducing agent, respectively (92, 93).”
Sharma, S., Chauhan, A., Ranjan, A., Mathkor, D. M., Haque, S., Ramniwas, S., Tuli, H. S., Jindal, T., & Yadav, V. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1403168 · Cited by 197
Fighting bacterial infections—Future treatment options
Fernebro, J. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.001 · Cited by 199
Immune Evasion by Staphylococcus aureus
de Jong, N. W. M., van Kessel, K. P. M., & van Strijp, J. A. G. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0061-2019 · Cited by 194
“Therefore, synthetic inhibitors of CrtM are interesting new virulence factor-based therapies that act by targeting the biosynthesis of staph-yloxanthin ( 174, 175).”
BackgroundXiao, J., Wang, S., Chen, L., Ding, X., Dang, Y., Han, M., Zheng, Y., Shen, H., Wu, S., Wang, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.021 · Cited by 189
Nikolic, P., & Mudgil, P. (2023) · Microorganisms · doi:10.3390/microorganisms11020259 · Cited by 179
“Its role as a virulence factor is as an antioxidant to protect the cell from the reactive oxygen species generated by the host immune system [76].”
BackgroundXiao, J., Li, W., Zheng, X., Qi, L., Wang, H., Zhang, C., Wan, X., Zheng, Y., Zhong, R., Zhou, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.015 · Cited by 180
Self-citationCurrent concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus
Watkins, R. R., David, M. Z., & Salata, R. A. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.043513-0 · Cited by 178
“A human squalene synthase inhibitor blocked staphyloxanthin biosynthesis in vitro, resulting in nonpigmented bacteria that were more susceptible to killing by human blood and clearance by the innate immune system in a mouse model (Liu et al., 2008).”
BackgroundAntivirulence as a new antibacterial approach for chemotherapy
Escaich, S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.06.022 · Cited by 173
A Very Early-Branching Staphylococcus aureus Lineage Lacking the Carotenoid Pigment Staphyloxanthin
Holt, D. C., Holden, M. T. G., Tong, S. Y. C., Castillo-Ramirez, S., Clarke, L., Quail, M. A., Currie, B. J., Parkhill, J., Bentley, S. D., Feil, E. J., et al. (2011) · Genome Biology and Evolution · doi:10.1093/gbe/evr078 · Cited by 173
“Inhibition of staphyloxanthin synthesis in vivo resulted in increased susceptibility of S. aureus to killing by human blood and to innate immune clearance in a mouse infection model (Liu 2008).”
BackgroundFresh Approaches to Anti-Infective Therapies
Nathan, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003081 · Cited by 163
“In vitro, the compound had no apparent effect on the bacteria, but in the infected host, it allowed the immune system to control the infection (35).”
BackgroundIdentification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii
Niehaus, T. D., Okada, S., Devarenne, T. P., Watt, D. S., Sviripa, V., & Chappell, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106222108 · Cited by 158
“Microbial forms of dihydrosqualene synthase, like CrtM, might also be considered an example of squalene synthase-like enzyme diversification (47, 48).”
BackgroundConsiderations and caveats in anti-virulence drug development
Maura, D., Ballok, A. E., & Rahme, L. G. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.06.001 · Cited by 159
The Role of Lipid Domains in Bacterial Cell Processes
Barák, I., & Muchová, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14024050 · Cited by 168
Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence
Chen, F., Di, H., Wang, Y., Cao, Q., Xu, B., Zhang, X. C., Yang, N., Liu, G., Yang, C., Xu, Y., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2003 · Cited by 164
Self-citationNewer antibacterial drugs for a new century
Devasahayam, G., Scheld, W. M., & Hoffman, P. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903505092 · Cited by 155
“An example of virulence factor-based therapy arises by the recent discovery of a cholesterol-reducing agent (BPH-652, a phosphonosulfonate), which is an inhibitor of MRSA [155].”
Painter, K. L., Strange, E., Parkhill, J., Bamford, K. B., Armstrong-James, D., & Edwards, A. M. (2015) · Infection and Immunity · doi:10.1128/iai.03016-14 · Cited by 153
“Previous work has suggested that SCVs should be more susceptible to H2O2 than wild-type bacteria due to the lack of staphyloxanthin pigment and reduced catalase activity in heme auxotrophs (19, 36, 37, 45).”
BackgroundDiscovery of a Small Molecule that Blocks Wall Teichoic Acid Biosynthesis in Staphylococcus aureus
Swoboda, J. G., Meredith, T. C., Campbell, J., Brown, S. L., Suzuki, T., Bollenbach, T., Malhowski, A. J., Kishony, R., Gilmore, M. S., & Walker, S. (2009) · ACS Chemical Biology · doi:10.1021/cb900151k · Cited by 152
Structure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“Recent successful stories include the discovery of nonsteroidal antagonists against the human androgen receptor [35] and the repurpose of cholesterol drugs to block Staphylococcus aureus virulence [36].”
BackgroundNatural Products That Target Virulence Factors in Antibiotic-Resistant Staphylococcus aureus
Wu, S.-C., Liu, F., Zhu, K., & Shen, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05595 · Cited by 158
Yoon, Y., Lee, H., Lee, S., Kim, S., & Choi, K. (2015) · Food Research International · doi:10.1016/j.foodres.2015.03.016 · Cited by 154
Llarrull, L. I., Fisher, J. F., & Mobashery, S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-09 · Cited by 186
“Furthermore, nontraditional anti-infection targets, such as inhibitors of resistance mechanisms, virulence factors, and other proteins involved in cell wall synthesis, are also emerging as alternative strategies (27, 53, 75, 103, 106, 109, 134, 180).”
BackgroundPerry, E. K., Meirelles, L. A., & Newman, D. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00620-w · Cited by 162
The Association of Virulence Factors with Genomic Islands
Sui, S. J. H., Fedynak, A., Hsiao, W., Langille, M. G. I., & Brinkman, F. S. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008094 · Cited by 169
“Our study provides lists of pathogen-associated genes that may encode good candidates for vaccine development or anti-virulence drug development [53,54].”
BackgroundMunguia, J., & Nizet, V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.003 · Cited by 140
“aureus pigment production, sensitizing the pathogen to ROS, neutrophil killing, and reducing the bacterial burden in kidneys of mice following systemic infection [51].”
Self-citationTargeting Isoprenoid Biosynthesis for Drug Discovery: Bench to Bedside
Oldfield, E. (2010) · Accounts of Chemical Research · doi:10.1021/ar100026v · Cited by 129
Self-citationLan, L., Cheng, A. G., Dunman, P. M., Missiakas, D. M., & He, C. (2010) · Journal of Bacteriology · doi:10.1128/jb.00928-09 · Cited by 130
“The increased pigmentation benefits bacteria for survival in certain environments (29, 30).”
BackgroundInfluentialResistance-resistant antibiotics
Oldfield, E., & Feng, X. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.10.007 · Cited by 132
Self-citationNeutrophil-generated oxidative stress and protein damage in Staphylococcus aureus
Beavers, W. N., & Skaar, E. P. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw060 · Cited by 143
Host-Directed Drug Targeting of Factors Hijacked by Pathogens
Schwegmann, A., & Brombacher, F. (2008) · Science Signaling · doi:10.1126/scisignal.129re8 · Cited by 150
“Cholesterol is also a potential target that may be exploited to protect against infection by Leishmania (67) and other intracellular parasites, such as Staphylococcus aureus (39), because it is needed for binding or internalization of the infectious agent, or activity of virulence factors (Fig.”
BackgroundHow to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Hansen, E., Woods, R. J., & Read, A. F. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001110 · Cited by 124
Silva, L. N., da Hora, G. C. A., Soares, T. A., Bojer, M. S., Ingmer, H., Macêdo, A. J., & Trentin, D. D. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-02712-1 · Cited by 133
Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics
Vale, P. F., Fenton, A., & Brown, S. P. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001769 · Cited by 119
Bloemendaal, A. L. A., Brouwer, E. C., & Fluit, A. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011841 · Cited by 119
Cho, H. S., Lee, J., Cho, M. H., & Lee, J. (2014) · Biofouling · doi:10.1080/08927014.2014.991319 · Cited by 115
“…reported, for example the inhibition of biofilm formation (Boles & Horswill 2008; Iwase et al. 2010), the inhibition of enterotoxins and hemolysins (Wyatt et al. 2010), the inhibition of staphyloxanthin production (Liu et al. 2008), and the disruption of bacterial quorum sensing (Park et al. 2007).”
BackgroundIndole and 7-benzyloxyindole attenuate the virulence of Staphylococcus aureus
Lee, J., Cho, H. S., Kim, J., Kim, J.-A., Banskota, S., Cho, M. H., & Lee, J. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4674-z · Cited by 115
“Staphyloxanthin acts as an antioxidant by enabling the detoxification of host-immune system-generated ROS such as the oxygen radical (O) and H2O2 (Clauditz et al. 2006; Liu et al. 2008).”
BackgroundMethodInfluentialStaphyloxanthin: a potential target for antivirulence therapy
Xue, L., Chen, Y. Y., Yan, Z., Lu, W., Wan, D., & Zhu, H. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s193649 · Cited by 116
“Three phosphonosulfonates blocked staphyloxanthin biosynthesis in vitro by inhibiting CrtM activity.(64) Four inhibitors of lipid metabolism could inhibit staphyloxanthin production because they inhibited the production of polyprenyl and acyl residue in the staphy-”
BackgroundMaxson, T., & Mitchell, D. A. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.09.069 · Cited by 129
Antivirulence Strategies for the Treatment of Staphylococcus aureus Infections: A Mini Review
Ford, C. A., Hurford, I. M., & Cassat, J. E. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.632706 · Cited by 115
“aureus CrtM with repurposed lipid-lowering medications targeting squalene synthase may be favorable in infected patients with hyperlipidemia (Sharma et al., 1998; Liu et al., 2008; Song et al., 2009; Lin et al., 2010).”
BackgroundLee, K.-Y., Lee, J., Kim, S. I., Cho, M. H., & Lee, J. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5903-4 · Cited by 119
The biochemical basis for structural diversity in the carotenoids of chlorophototrophic bacteria
Maresca, J. A., Graham, J. E., & Bryant, D. A. (2008) · Photosynthesis Research · doi:10.1007/s11120-008-9312-3 · Cited by 111
“It is noteworthy that inhibitors of cholesterol biosynthesis block carotenoid biosynthesis in staphylococci (Liu et al. 2008), and such inhibitors might also be effective in blocking carotenoid production in heliobacteria.”
A Biosurfactant‐Inspired Heptapeptide with Improved Specificity to Kill MRSA
Liu, Y., Ding, S., Dietrich, R., Märtlbauer, E. P., & Zhu, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201609277 · Cited by 113
Kane, T., Carothers, K. E., & Lee, S. W. (2018) · Current Drug Targets · doi:10.2174/1389450117666161128123536 · Cited by 114
Ong, J. S., Taylor, T. D., Yong, C. C., Khoo, B. Y., Sasidharan, S., Choi, S. B., Ohno, H., & Liong, M. T. (2019) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9505-9 · Cited by 107
Can β-Lactam Antibiotics Be Resurrected to Combat MRSA?
Foster, T. J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.06.005 · Cited by 117
Song, Y., Liu, C.-I., Lin, F., No, J. H., Hensler, M. E., Liu, Y.-L., Jeng, W. Y., Low, J., Liu, G. Y., Nizet, V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9001764 · Cited by 106
Self-citationMetabolic sensor governing bacterial virulence in Staphylococcus aureus
Ding, Y., Liu, X., Chen, F., Di, H., Xu, B., Zhou, L., Deng, X., Wu, M., Yang, C., & Lan, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411077111 · Cited by 116
Wang, Z., Yang, Q., Wang, X., Li, R., Qiao, H., Ma, P.-A., Sun, Q., & Zhang, H. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.044 · Cited by 101
Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections
Zhu, J., Xie, R., Gao, R., Zhao, Y., Yodsanit, N., Zhu, M., Burger, J. C., Ye, M., Tong, Y., & Gong, S. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01648-8 · Cited by 118
Productive steps toward an antimicrobial targeting virulence
Barczak, A. K., & Hung, D. T. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.06.012 · Cited by 115
A Review of Antibacterial Candidates with New Modes of Action
Butler, M. S., Vollmer, W., Goodall, E. C. A., Capon, R. J., Henderson, I. R., & Blaskovich, M. A. T. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00218 · Cited by 112
Tong, S. Y. C., Chen, L. F., & Fowler, V. G. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0300-x · Cited by 122
“aureus in a murine intra-peritoneal sepsis model, although no mention is made of an impact on murine survival [93].”
BackgroundCampbell, J., Singh, A. K., Swoboda, J. G., Gilmore, M. S., Wilkinson, B. J., & Walker, S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05938-11 · Cited by 110
Czyż, D. M., Potluri, L., Jain‐Gupta, N., Riley, S. P., Martinez, J. J., Steck, T. L., Crosson, S., Shuman, H. A., & Gabay, J. E. (2014) · mBio · doi:10.1128/mbio.01534-14 · Cited by 98
Antibiotics as Instigators of Microbial Dysbiosis: Implications for Asthma and Allergy
Wypych, T. P., & Marsland, B. J. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.02.008 · Cited by 99
Lu, H., Tu, C., Zhou, T., Zhang, W., Zhan, Y., Ding, J., Wu, X., Yang, Z., Cao, W., Deng, L., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135130 · Cited by 96
Sen, S., Johnson, S. R., Song, Y., Sirobhushanam, S., Tefft, R., Gatto, C., & Wilkinson, B. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165300 · Cited by 100
“Staphyloxanthin has drawn considerable attention in recent years as a possible virulencefactor by detoxifying reactive oxygen species produced by phagocytic cells [22,23], and as a potential target for antistaphylococcal chemotherapy [24].”
Self-citationBioorganometallic mechanism of action, and inhibition, of IspH
Wang, W., Wang, K., Liu, Y.-L., No, J., Li, J., Nilges, M. J., & Oldfield, E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911087107 · Cited by 93
“On the other hand, propargyl diphosphate (9) was a more potent IspH inhibitor (Fig.”
BackgroundSelf-citationKaittanis, C., Nath, S., & Perez, J. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003253 · Cited by 93
Johnston, I., Osborn, L. J., Markley, R. L., McManus, E. A., Kadam, A., Schultz, K. B., Nagajothi, N., Ahern, P. P., Brown, J. M., & Claesen, J. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00226-3 · Cited by 99
“aureus infections [16].”
Leejae, S., Hasap, L., & Voravuthikunchai, S. P. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.047316-0 · Cited by 92
“Liu et al. (2008) recently observed that the crystal structure of S. aureus CrtM is very similar to that of human SQS used in cholesterol biosynthesis in humans (Liu et al., 2008).”
BackgroundInfluentialLee, J. H., Kim, Y. ‐., & Lee, J. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13602 · Cited by 98
“Whole blood killing assay This assay was performed as previously described (Liu et al. 2008).”
MethodDong, P., Mohammad, H. T., Hui, J., Leanse, L. G., Li, J., Liang, L., Dai, T., Seleem, M. N., & Cheng, J. (2019) · Advanced Science · doi:10.1002/advs.201900030 · Cited by 92
Mechanism of action and inhibition of dehydrosqualene synthase
Lin, F., Liu, C.-I., Liu, Y.-L., Zhang, Y., Wang, K., Jeng, W. Y., Ko, T., Cao, R., Wang, A. H. ‐., & Oldfield, E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010907107 · Cited by 92
“is the alkene (acceptor)? How do PSPP and dehydrosqualene (DHS) bind to CrtM (or SQS)? And where do the diphosphates ionize? In our work on CrtM (10), we used the nonreactive substrate analog, S-thiolo-farnesyl diphosphate (FSPP), to define two prenyl diphosphate binding sites: S1 and S2.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Liu, Chia-I
- Liu, George Y.
- Song, Yongcheng
- Nizet, Victor
- Wang, Andrew H.-J.
- Oldfield, Eric
- Venue
- Science
- Published
- 2008-03-07
- Volume
- 319
- Issue
- 5868
- Pages
- 1391-1394
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2747771
- OpenAlex
- W1986930831
- Cited by
- 490
- References
- 16
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 34 · 2023: 26 · 2022: 24 · 2021: 25 · 2020: 28 · 2019: 31 · 2018: 28 · 2017: 40 · 2016: 23 · 2015: 17 · 2014: 32 · 2013: 26 · 2012: 33
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM065307, GM073216, R01GM073216, GM65307)
- National Institute of Allergy and Infectious Diseases (AI07482)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 051796, R01HD051796)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Metabolism and Applications
- Keywords
- Staphylococcus aureus, cholesterol synthesis inhibition, CRTM, squalene synthase inhibitors, methicillin-resistant Staphylococcus aureus, bacterial virulence, reactive oxygen species resistance, crystal structure
- MeSH terms
- Amino Acid Sequence, Animals, Anti-Bacterial Agents, Bacterial Proteins, Cell Line, Cholesterol, Enzyme Inhibitors, Humans, Molecular Sequence Data, Organothiophosphorus Compounds, Polyisoprenyl Phosphates, Sesquiterpenes, Farnesyl-Diphosphate Farnesyltransferase, Staphylococcal Infections, Staphylococcus aureus, Virulence, Protein Structure, Secondary, Crystallography, X-Ray, Xanthophylls, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.